Mizuho Securities Reiterates Buy Following Ventas' (VTR) 35% YTD Stock Increase PT to $84
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ventas Reports 2016 Second Quarter Results
July 29, 2016 6:53 AM EDTContinued Strong Track Record of Earnings Growth Enhanced Companys Credit Profile Through Excellent Capital Markets Execution Announced $1.5 Billion Acquisition of Wexford Life Science and Medical Real Estate
CHICAGO--(BUSINESS WIRE)-- Ventas, Inc. (NYSE: VTR) (Ventas or the Company) today announced strong earnings on a healthy balance sheet for the second quarter of 2016, driven by excellent performance from the Companys high-quality healthcare and senior living properties and accretive acquisitions:
Income from continuing operations per diluted common share for... More